Fig. 1: Forest plot of mean predicted survival probability and 95% CI – prespecified subgroup analyses by baseline EBOV GP binding antibody concentration, sex, age category, race, and region; PPI analysis set. | npj Vaccines

Fig. 1: Forest plot of mean predicted survival probability and 95% CI – prespecified subgroup analyses by baseline EBOV GP binding antibody concentration, sex, age category, race, and region; PPI analysis set.

From: Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Fig. 1

This analysis was based on the pooled data of healthy adults (aged 18-50 years) vaccinated with Ad26.ZEBOV, MVA-BN-Filo in a 56-day interval in five clinical studies (EBL2001, EBL2002, EBL3001, EBL3002, and EBL3003) using a logistic regression model based on NHP data from the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval. Mean predicted survival probability and the 95% bootstrapped CI are reported. CI confidence interval, EBOV Ebola virus, ELISA enzyme-linked immunosorbent assay, EU enzyme-linked immunosorbent assay units, GMC geometric mean concentration, GP glycoprotein, LLOQ lower limit of quantification (36.11 EU/mL), N number of participants with data, NHP non-human primate, PPI per-protocol immunogenicity, vertical dashed line = mean predicted survival probability from primary analysis including all participants. *The subgroup analyses excluding the participants from clinical study EBL3001 and the stratification by baseline EBOV GP ELISA level are described in more detail in the Supplementary Results.

Back to article page